Sangamo Biosciences, Inc. (NASDAQ:SGMO)

CAPS Rating: 2 out of 5

The Company deals in the research, development and commercialization of DNA-binding proteins for the therapeutic regulation and modification of disease-related genes.


Player Avatar zzlangerhans (99.76) Submitted: 12/1/2008 2:35:31 PM : Underperform Start Price: $2.20 SGMO Score: +3.00

Sangamo. The very name brings bile to my throat and sets an artery to throbbing in my temple. Much like the name Alamo might to a Texan. I knew this company was crap. I knew zinc fingers were bull. But I wanted to play them like a fish, letting them out and reeling them in, until score leadership was mine. They hit a low point and I green thumbed them. I never thought the losers couldn't even spin a single positive phase II trial. Now I'm just going to forget about this underperform until they go bankrupt. Even if it takes ten years.

Featured Broker Partners